Improved Speed and Accuracy in Immunogenicity Testing
Newsletter

Improved Speed and Accuracy in Immunogenicity Testing

Introducing iLite® IFN FAST second-generation assay-ready cells

Effective bioassays are crucial in pharmaceutical development for assessing potency and detecting neutralizing antibodies in immunogenicity studies.

 Our iLite IFN FAST second-generation cells offer shorter incubation times, Renilla normalization, and an assay-ready format for a rapid and convenient workflow. These advancements streamline your processes and improve data reliability, enabling you to make informed decisions faster and more effectively. 

Speed up your neutralizing antibody detection

iLite Type I IFN FAST detects neutralizing antibodies towards interferon beta with a shorter assay time (5 h incubation) than first-generation iLite Type I IFN (18 h incubation).  

This acceleration not only speeds up the overall development timeline but also allows for more timely adjustments and improvements to therapeutic strategies.

Gain confidence in data accuracy

iLite Type I IFN FAST offers the opportunity to normalize type I IFN-induced firefly luciferase activity using constitutively expressed renilla luciferase.

This normalization process enhances the accuracy and consistency of NAbs detection, ensuring that results are more dependable and reproducible.

 

Develop drugs more efficiently and effectively

By integrating faster NAb antibody detection with Renilla normalization, the second-generation iLite cells offer a powerful tool for pharmaceutical development.

iLite Type I IFN FAST cells come in an assay-ready format, eliminating the need for time-consuming cell culture procedures, and saving both time and money.

You can start the experiments immediately without the hassle of cell thawing, counting, or passaging.